Bone Biologics Corporation filed a current report to share that its Chief Executive Officer issued a letter to stockholders. On September 4, 2025, the company released a press release discussing this CEO letter, and that press release is attached as Exhibit 99.1 to the report and incorporated by reference. The company’s common stock and related warrants trade on the Nasdaq Capital Market under the symbols BBLG and BBLGW, respectively.
Bone Biologics Corporation is updating its shelf registration statement on Form S-3 to carry forward $17,592,964 of previously registered but unsold securities under Rule 415(a)(6). The company states that, upon effectiveness of this new registration, the offering of these unsold securities under its prior registration statement (File No. 333-265872) will be deemed terminated and the previously paid $1,630.87 filing fee will be applied to this filing. This Amendment No. 1 is being filed solely to add the consent of its independent registered public accounting firm as Exhibit 23.1, with all other parts of the registration statement unchanged.
Bone Biologics (Nasdaq: BBLG / BBLGW) filed an 8-K (Item 8.01) reporting that Nasdaq’s Listing Qualifications Department confirmed on June 25 2025 the company has regained compliance with Listing Rule 5550(a)(2), which requires a minimum bid price of $1 per share. The confirmation removes the prior deficiency notice and the immediate risk of delisting from the Nasdaq Capital Market.
The disclosure, delivered via a press release furnished as Exhibit 99.1, contains no additional financial data, share issuances, or operational updates. By maintaining its listing, the company preserves liquidity, institutional access, and market visibility—factors critical to future capital-raising efforts.